MA49822A - Combinaison pharmaceutique comprenant du ponesimod - Google Patents
Combinaison pharmaceutique comprenant du ponesimodInfo
- Publication number
- MA49822A MA49822A MA049822A MA49822A MA49822A MA 49822 A MA49822 A MA 49822A MA 049822 A MA049822 A MA 049822A MA 49822 A MA49822 A MA 49822A MA 49822 A MA49822 A MA 49822A
- Authority
- MA
- Morocco
- Prior art keywords
- ponesimod
- pharmaceutical combination
- combination including
- pharmaceutical
- including ponesimod
- Prior art date
Links
- LPAUOXUZGSBGDU-ULCCENQXSA-N (5z)-5-[[3-chloro-4-[(2r)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=NCCC)S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-ULCCENQXSA-N 0.000 title 1
- 229950009275 ponesimod Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017055994 | 2017-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49822A true MA49822A (fr) | 2020-06-17 |
Family
ID=61655772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049822A MA49822A (fr) | 2017-03-14 | 2018-03-13 | Combinaison pharmaceutique comprenant du ponesimod |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US11723896B2 (https=) |
| EP (1) | EP3595657A1 (https=) |
| JP (3) | JP7281406B2 (https=) |
| KR (1) | KR102574562B1 (https=) |
| CN (1) | CN110381942B (https=) |
| AU (2) | AU2018233109B2 (https=) |
| BR (1) | BR112019018894A2 (https=) |
| CA (1) | CA3056301C (https=) |
| CL (1) | CL2019002525A1 (https=) |
| CO (1) | CO2019008510A2 (https=) |
| CR (1) | CR20190464A (https=) |
| DO (1) | DOP2019000257A (https=) |
| EA (1) | EA201992117A1 (https=) |
| EC (1) | ECSP19073317A (https=) |
| IL (1) | IL269239B2 (https=) |
| JO (1) | JOP20190207A1 (https=) |
| MA (1) | MA49822A (https=) |
| MX (1) | MX390941B (https=) |
| NI (1) | NI201900092A (https=) |
| PE (1) | PE20191489A1 (https=) |
| PH (1) | PH12019502110A1 (https=) |
| SG (1) | SG11201907308UA (https=) |
| UA (1) | UA125756C2 (https=) |
| WO (1) | WO2018167030A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL178596C (nl) | 1975-06-05 | 1986-04-16 | Hoechst Ag | Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden. |
| DE2854439A1 (de) | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
| US5268382A (en) | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
| DE3534440A1 (de) | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
| CA2400290A1 (en) * | 2000-02-15 | 2001-08-23 | Teva Pharmaceutical Industries Ltd. | A method for synthesizing leflunomide |
| EP1381356B1 (en) | 2001-04-05 | 2008-05-28 | Aventis Pharmaceuticals Inc. | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| GB0123571D0 (en) | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| US6894184B2 (en) | 2003-03-18 | 2005-05-17 | Aventis Pharma Deutschland Gmbh | Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides |
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| PT1689726E (pt) | 2003-11-21 | 2010-12-09 | Actelion Pharmaceuticals Ltd | Derivados de 5-(benz-(z)-ilideno)-tiazolidin-4-ona como agentes imunossupressores |
| CA2584655A1 (en) | 2004-10-19 | 2006-04-27 | Aventis Pharmaceuticals Inc. | Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
| DE102006017896A1 (de) | 2006-04-13 | 2007-10-25 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Leflunomid enthaltende pharmazeutische Zusammensetzungen |
| US8263780B2 (en) | 2006-11-23 | 2012-09-11 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| HUE033168T2 (en) | 2008-03-17 | 2017-11-28 | Actelion Pharmaceuticals Ltd | Dosage regimen for selective SIP1 receptor agonist |
| GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| US20120172427A1 (en) | 2009-09-18 | 2012-07-05 | Sanofi | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide tablet formulations with improved stability |
| EP2598126A2 (en) | 2010-07-30 | 2013-06-05 | Saint Louis University | Methods of treating pain |
| WO2012018704A1 (en) | 2010-08-02 | 2012-02-09 | Sanofi-Aventis U.S. Llc | Use of teriflunomide for treating multiple sclerosis |
| EP2692343A1 (en) | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| MX350891B (es) | 2012-08-17 | 2017-09-22 | Actelion Pharmaceuticals Ltd | Proceso para la preparacion de (2z,5z)-5-(3-cloro-4-((r)-2,3-dihid roxipropoxi) bencilideno)-2-(propilimino)-3-(o-tolil) tiazolidin-4-ona y el intermediario usado en dicho proceso. |
| WO2016079687A1 (en) | 2014-11-18 | 2016-05-26 | Lupin Limited | Oral pharmaceutical composition of teriflunomide |
| MA41139B1 (fr) | 2014-12-11 | 2026-02-27 | Laboratoires Juvise Pharmaceuticals | Combinaison pharmaceutique comprenant du ponesimod et son utilisation dans le traitement de la sclérose en plaque |
| EP4056179A1 (en) | 2014-12-11 | 2022-09-14 | Actelion Pharmaceuticals Ltd | Dosing regimen for ponesimod, a selective s1p1 receptor agonist |
| CA2987798A1 (en) | 2015-06-18 | 2016-12-22 | Matinas Biopharma Nanotechnologies, Inc. | Compositions and methods for treating inflammatory disease or conditions |
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
-
2017
- 2017-06-16 JO JOP/2019/0207A patent/JOP20190207A1/ar unknown
-
2018
- 2018-03-13 UA UAA201910123A patent/UA125756C2/uk unknown
- 2018-03-13 BR BR112019018894A patent/BR112019018894A2/pt not_active Application Discontinuation
- 2018-03-13 CR CR20190464A patent/CR20190464A/es unknown
- 2018-03-13 MA MA049822A patent/MA49822A/fr unknown
- 2018-03-13 US US16/494,163 patent/US11723896B2/en active Active
- 2018-03-13 CN CN201880017102.0A patent/CN110381942B/zh active Active
- 2018-03-13 MX MX2019010874A patent/MX390941B/es unknown
- 2018-03-13 WO PCT/EP2018/056185 patent/WO2018167030A1/en not_active Ceased
- 2018-03-13 SG SG11201907308UA patent/SG11201907308UA/en unknown
- 2018-03-13 EP EP18711299.0A patent/EP3595657A1/en active Pending
- 2018-03-13 PE PE2019001845A patent/PE20191489A1/es unknown
- 2018-03-13 EA EA201992117A patent/EA201992117A1/ru unknown
- 2018-03-13 JP JP2019549459A patent/JP7281406B2/ja active Active
- 2018-03-13 AU AU2018233109A patent/AU2018233109B2/en active Active
- 2018-03-13 CA CA3056301A patent/CA3056301C/en active Active
- 2018-03-13 KR KR1020197026599A patent/KR102574562B1/ko active Active
-
2019
- 2019-08-05 CO CONC2019/0008510A patent/CO2019008510A2/es unknown
- 2019-09-03 CL CL2019002525A patent/CL2019002525A1/es unknown
- 2019-09-10 IL IL269239A patent/IL269239B2/en unknown
- 2019-09-11 NI NI201900092A patent/NI201900092A/es unknown
- 2019-09-13 PH PH12019502110A patent/PH12019502110A1/en unknown
- 2019-10-08 DO DO2019000257A patent/DOP2019000257A/es unknown
- 2019-10-10 EC ECSENADI201973317A patent/ECSP19073317A/es unknown
-
2022
- 2022-12-21 JP JP2022204487A patent/JP2023030091A/ja active Pending
-
2023
- 2023-06-27 US US18/341,853 patent/US12527772B2/en active Active
- 2023-11-29 AU AU2023274118A patent/AU2023274118B2/en active Active
-
2024
- 2024-04-18 JP JP2024067486A patent/JP2024096962A/ja active Pending
-
2025
- 2025-12-22 US US19/429,084 patent/US20260108501A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3817722A4 (en) | PHARMACEUTICAL COMPOSITIONS WITH MELOXICAM | |
| EP3493799A4 (en) | CANNABIS | |
| EP3493798A4 (en) | CANNABIS | |
| EP3645118C0 (en) | SIMULATION-BASED DRUG TREATMENT PLANNING | |
| MA47816A (fr) | Composition pharmaceutique comprenant du sélexipag | |
| EP3641771A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| DK3655017T3 (da) | Farmaceutisk sammensætning | |
| MA43705A (fr) | Formulation pharmaceutique | |
| EP3689892A4 (en) | RADIOACTIVE MEDICINAL PRODUCT | |
| EP3452075A4 (en) | OPHTHALMIC PHARMACEUTICAL COMPOSITION | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| EP3603642A4 (en) | PHARMACEUTICAL PREPARATION | |
| IL283900A (en) | Pharmaceutical combinations | |
| MA49822A (fr) | Combinaison pharmaceutique comprenant du ponesimod | |
| EP3402470A4 (en) | STABLE PHARMACEUTICAL COMPOSITION | |
| MA47516A (fr) | Composition pharmaceutique | |
| EP3539121C0 (en) | FAULT-TOLERANT DISPLAY DEVICE | |
| EP3383371A4 (en) | PHARMACEUTICAL FORMULATION | |
| EP3646866A4 (en) | PHARMACEUTICAL PREPARATION | |
| MA49837A (fr) | Compositions pharmaceutiques | |
| EP3638322A4 (en) | DECONTAMINATION FORMULATION | |
| DK3728220T3 (da) | Farmaceutiske forbindelser | |
| EP3646863A4 (en) | PHARMACEUTICAL COMPOSITION | |
| EP3646867A4 (en) | PHARMACEUTICAL COMPOSITION | |
| MA45126A (fr) | Formulation pharmaceutique antifongique |